How has been the historical performance of Parmax Pharma?

Answer:The historical performance of Parmax Pharma shows significant fluctuations in key financial metrics over the years. Breakdown: Parmax Pharma's net sales have seen a notable increase from Mar'24 at 11.05 Cr to Mar'25 at 28.20 Cr, following a dip in Mar'23 at 15.42 Cr and Mar'22 at 18.25 Cr. However, the total expenditure also rose sharply to 27.95 Cr in Mar'25 from 14.43 Cr in Mar'24, leading to a slim operating profit of 0.25 Cr in Mar'25, a recovery from a loss of 3.38 Cr in the previous year. Despite this, the company reported a profit before tax of -2.40 Cr in Mar'25, an improvement from -5.66 Cr in Mar'24, but still indicative of ongoing challenges. The profit after tax also remained negative at -2.09 Cr in Mar'25, although less severe than the -5.75 Cr recorded in Mar'24. The company's reserves have turned negative, dropping to -6.44 Cr in Mar'25 from -4.35 Cr in Mar'24, reflecting a deteriorating financial position. Total assets increased to 18.56 Cr in Mar'25 from 15.33 Cr in Mar'24, while total liabilities also rose to 18.56 Cr in Mar'25 from 15.33 Cr in Mar'24, indicating a growing debt burden. Cash flow from operating activities remained stagnant at 0.00 Cr in Mar'24 and Mar'23, highlighting liquidity issues. Overall, while there are signs of revenue growth, Parmax Pharma continues to face significant profitability and financial stability challenges.